Index by Author

September/October 2016; Volume 70,Issue 5

  1. Bakhshayeshi, Meisam

    1. Session 4.1: Case Studies of Application of Generic Claims and QbD for Viral Clearance
      Rachel Specht and Meisam Bakhshayeshi
      PDA Journal of Pharmaceutical Science and Technology September 2016, 70 (5) 462-469; DOI: https://doi.org/10.5731/pdajpst.2016.006957
    2. Session 4.2: Viral Spiking, Viral Preparation, and Upstream Risk Mitigation Strategies
      Meisam Bakhshayeshi and Rachel Specht
      PDA Journal of Pharmaceutical Science and Technology September 2016, 70 (5) 470-476; DOI: https://doi.org/10.5731/pdajpst.2016.006965

  2. Blumel, Johannes

    1. Session 5: Conference Summary: Key Discussion and Outcomes, Pending Questions, and Proposed Experiments
      Glen Bolton and Johannes Blümel
      PDA Journal of Pharmaceutical Science and Technology September 2016, 70 (5) 477-481; DOI: https://doi.org/10.5731/pdajpst.2016.006973
    2. Session 2: Company-Specific Data on Cycled Resin Testing
      Johannes Blümel and Kurt Brorson
      PDA Journal of Pharmaceutical Science and Technology September 2016, 70 (5) 428-442; DOI: https://doi.org/10.5731/pdajpst.2016.006924

  3. Bolton, Glen

    1. Session 5: Conference Summary: Key Discussion and Outcomes, Pending Questions, and Proposed Experiments
      Glen Bolton and Johannes Blümel
      PDA Journal of Pharmaceutical Science and Technology September 2016, 70 (5) 477-481; DOI: https://doi.org/10.5731/pdajpst.2016.006973
    2. Introduction: Proceedings of the 2015 Viral Clearance Symposium
      Glen Bolton and Rich Levy
      PDA Journal of Pharmaceutical Science and Technology September 2016, 70 (5) 409; DOI: https://doi.org/10.5731/pdajpst.2016.006874

  4. Brorson, Kurt

    1. Session 2: Company-Specific Data on Cycled Resin Testing
      Johannes Blümel and Kurt Brorson
      PDA Journal of Pharmaceutical Science and Technology September 2016, 70 (5) 428-442; DOI: https://doi.org/10.5731/pdajpst.2016.006924

  5. Buhlmann, Bob

    1. PDA Points To Consider: Fundamental Concepts in Data Integrity
      Bob Buhlmann, Madlene Dole and Zena Kaufmann
      PDA Journal of Pharmaceutical Science and Technology September 2016, 70 (5) 482-488; DOI: https://doi.org/10.5731/pdajpst.2016.007062

  6. Chen, Dayue

    1. Session 3.1: Protein A, Hydroxyapatite, and Mixed-Mode Chromatography
      Dayue Chen
      PDA Journal of Pharmaceutical Science and Technology September 2016, 70 (5) 443-450; DOI: https://doi.org/10.5731/pdajpst.2016.006932

  7. Dole, Madlene

    1. PDA Points To Consider: Fundamental Concepts in Data Integrity
      Bob Buhlmann, Madlene Dole and Zena Kaufmann
      PDA Journal of Pharmaceutical Science and Technology September 2016, 70 (5) 482-488; DOI: https://doi.org/10.5731/pdajpst.2016.007062

  8. Gallo, Christopher

    1. Session 3.2: Viral Clearance of Emerging Unit Operations: Membrane Chromatography, Other Methods, Etc.
      Christopher Gallo
      PDA Journal of Pharmaceutical Science and Technology September 2016, 70 (5) 451-461; DOI: https://doi.org/10.5731/pdajpst.2016.006940

  9. Kaufmann, Zena

    1. PDA Points To Consider: Fundamental Concepts in Data Integrity
      Bob Buhlmann, Madlene Dole and Zena Kaufmann
      PDA Journal of Pharmaceutical Science and Technology September 2016, 70 (5) 482-488; DOI: https://doi.org/10.5731/pdajpst.2016.007062

  10. Levy, Rich

    1. Introduction: Proceedings of the 2015 Viral Clearance Symposium
      Glen Bolton and Rich Levy
      PDA Journal of Pharmaceutical Science and Technology September 2016, 70 (5) 409; DOI: https://doi.org/10.5731/pdajpst.2016.006874
« Previous (Pages : 1 2 ... 2) Next »
Back to top

In This Issue